This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Humana (HUM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Molina (MOH) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
UnitedHealth (UNH) Unit Chosen to Aid Missouri Medicaid Members
by Zacks Equity Research
UnitedHealth Group's (UNH) unit, UnitedHealthcare, has been selected by Missouri and entrusted to administer the MO HealthNet Managed Care Program to serve the state's Medicaid beneficiaries.
Select Medical (SEM) Shares Up on Q1 Earnings & Revenue Beat
by Zacks Equity Research
Select Medical's (SEM) first-quarter earnings benefit from higher patient visits and sound segmental contributions to revenues, partly offset by elevated labor expenses.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.
Ensign Group (ENSG) Down 5.1% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter results highlight sound contributions from the Skilled Services and Standard Bearer segments, partly offset by a rise in expenses mainly stemming from a higher cost of services.
Medtronic (MDT) Global Business Gains Ground, Volume Woes Stay
by Zacks Equity Research
Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.
Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure
by Zacks Equity Research
Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Molina (MOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Molina Healthcare (MOH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.